stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.81
1.22
−4.69%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Debt to equity
Caris Life Sciences,�Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.7× from fiscal 2025 (0.7×). That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.7× | — |
| FY2024 | −0.2× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.7× | 3.34% |
| Mar 2026 | 0.6× | (2.07%) |
| Dec 2025 | 0.7× | (16.58%) |
| 7 more quarters | Free account |
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| IBRX ImmunityBio, Inc. compare | −0.7× |
| CYTK Cytokinetics, Incorporated compare | −0.5× |
| KRYS Krystal Biotech, Inc. compare | 0.0× |
| CAI Caris Life Sciences,�Inc. | 0.0× |
| SYRE Spyre Therapeutics, Inc. compare | 0.0× |
| PTGX Protagonist Therapeutics, Inc. compare | 0.0× |
| TWST Twist Bioscience Corporation compare | 0.0× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 0.5× |
| TGTX TG Therapeutics, Inc. compare | 1.2× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Shares outstanding
- Book value per share
- The full statement